Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MRNA stock price vs GILD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GILD's multiple
Needs GILD P/S.
Implied fair value · at MRNA's multiple
Needs MRNA P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Moderna, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
MRNA vs PFE
JOHNSON & JOHNSON
MRNA vs JNJ
AMGEN INC
MRNA vs AMGN
NOVAVAX INC
MRNA vs NVAX
VERTEX PHARMACEUTICALS INC / MA
MRNA vs VRTX
AbbVie Inc.
MRNA vs ABBV
BRISTOL MYERS SQUIBB CO
MRNA vs BMY
Merck & Co., Inc.
MRNA vs MRK
REGENERON PHARMACEUTICALS, INC.
MRNA vs REGN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MRNA can reverse its -39.9% revenue decline and meaningfully improve margins, then holding or buying may make sense; otherwise, the data favors reducing exposure because MRNA’s current price is far above GILD-implied value and its profitability is much weaker than GILD’s.
The implied price of $27.03 is 50.7% below MRNA’s current price of $54.82, and GILD-implied range is tightly centered at $26.74, pointing to a large valuation disconnect. The gap is driven by MRNA’s 11.3x P/S and 10.2x EV/Revenue versus GILD’s 5.5x P/S and 6.2x EV/Revenue, while MRNA also has negative earnings and cash-flow-related weakness.
Supporting Metrics
